Ishara Investments LP bought a new stake in Immatics N.V. (NASDAQ:IMTX – Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 80,000 shares of the company’s stock, valued at approximately $840,000. Ishara Investments LP owned about 0.07% of Immatics at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently modified their holdings of IMTX. Bank of America Corp DE lifted its stake in shares of Immatics by 166.0% in the 4th quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock valued at $25,000 after acquiring an additional 2,231 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Immatics by 31.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 198,769 shares of the company’s stock valued at $1,069,000 after acquiring an additional 47,590 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in shares of Immatics by 105.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 78,123 shares of the company’s stock valued at $420,000 after acquiring an additional 40,058 shares during the last quarter. Engineers Gate Manager LP bought a new stake in shares of Immatics in the 2nd quarter valued at about $124,000. Finally, Sofinnova Investments Inc. lifted its stake in shares of Immatics by 44.1% in the 2nd quarter. Sofinnova Investments Inc. now owns 2,240,528 shares of the company’s stock valued at $12,054,000 after acquiring an additional 686,224 shares during the last quarter. Institutional investors own 64.41% of the company’s stock.
Immatics Price Performance
IMTX opened at $9.52 on Thursday. The business has a 50 day simple moving average of $10.72 and a two-hundred day simple moving average of $10.22. The firm has a market capitalization of $1.28 billion, a price-to-earnings ratio of -4.78 and a beta of 1.30. Immatics N.V. has a one year low of $5.05 and a one year high of $12.41.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently weighed in on IMTX shares. Chardan Capital reissued a “buy” rating and issued a $25.00 target price on shares of Immatics in a research note on Tuesday, May 19th. TD Cowen started coverage on Immatics in a research note on Tuesday, April 28th. They issued a “buy” rating for the company. Weiss Ratings reissued a “sell (d)” rating on shares of Immatics in a research note on Tuesday, June 9th. Wall Street Zen lowered Immatics from a “hold” rating to a “sell” rating in a research note on Saturday, May 2nd. Finally, Jefferies Financial Group started coverage on Immatics in a research report on Monday, March 16th. They set a “buy” rating and a $18.00 price target for the company. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $20.80.
Get Our Latest Research Report on Immatics
Immatics Profile
Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.
At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.
Further Reading
- Five stocks we like better than Immatics
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Want to see what other hedge funds are holding IMTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immatics N.V. (NASDAQ:IMTX – Free Report).
Receive News & Ratings for Immatics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immatics and related companies with MarketBeat.com's FREE daily email newsletter.
